Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hummingbird Bioscience Appoints New CMO and COO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Hummingbird Bioscience Appoints New CMO and COO

Names Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Hummingbird Bioscience, a precision biotherapeutics company, has appointed Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.

Dr. Kon Yew Kwek, Chief Medical Officer

Kwek is promoted to Chief Medical Officer, from Senior Vice President of Clinical Development. He joined the company in 2022 and brings two decades of experience from Akeso Biopharma, Eli Lilly and IQVIA and clinical practice. He will lead the company’s clinical development from Singapore.

“I look forward to the next milestones in our clinical programs and progressing more of our pre-clinical pipeline to the clinic,” said Kwek.

Dr. Lisa Ooi, Chief Operating Officer

Ooi is promoted to Chief Operating Officer, from Senior Vice President of Strategy. She joined the company in 2022 and brings two decades of experience from Singapore’s government agencies and biopharma industry, including the Economic Development Board, Agency for Science, Technology and Research (A*STAR), ASLAN Pharmaceuticals and Bayer.

“I am delighted to lead the team’s strategy towards its next phase of growth, building upon our strong scientific capabilities and commitment to deeply understanding tumor biology. With our proprietary antibody and dual-payload ADC platform technologies, I look forward to what we will achieve in the coming year,” said Ooi.

Related News

Last year, Hummingbird Bioscience named Angèle Maki as Chief Business Officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters